- HK$84.10bn
- HK$79.10bn
- CNY3.06bn
Brief: Akeso Says NMPA Accepted Supplemental New Drug Application For Cadonilimab
Biological products developer Akeso falls on discounted share sale
Brief: Akeso Announces Placing Of New Shares Under General Mandate
Brief: Akeso Says FY Profit RMB1,942.4 Million
Brief: Akeso Sees Profit Of Not Less Than RMB1.85 Billion During Year
Brief: Akeso Says Unit To Purchase 35% Stake In Ad Pharmaceuticals For Rmb267.4 Mln
Brief: Akeso Presented Promising Results Of Cadonilimab And Lenvatinib In Combination With Tace In Uhcc At 2024 Asco Gi
Brief: Akeso Says NMPA Accepted Supplemental New Drug Application For Cadonilimab In Combination With Chemotherapy As First-Line Treatment For Gastric Cancer
Advisory: Alert wrongly tagged to Lenovo Group Ltd withdrawn
Brief: Akeso's Cadonilimab Met Primary Endpoint Of Progression-Free Survival In Phase III Trial For First-Line Treatment Of Recurrent/Metastatic Cervical Cancer In All-Comer Patients
China's Akeso rises on progress of cervical cancer drug
Brief: Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint
China's Akeso hits 9-month peak on progress of new drug development
Brief: Shenzhen Capital Group's Long Position In H-Share Of Akeso Falls To 4.99% - Filing
Brief: Journal Of Thoracic Oncology Published Promising Results
Brief: Phase 1a/1b Study Results of Akeso's PD-1/CTLA-4 Bispecific Antibody Published in Cell Reports Medicine
Brief: Akeso And Remegen Collaborates On Clinical Study Exploring The Potential Of Pd-1/Ctla-4 Bispecific Antibody With Her-2 Adc Combination Therapy In Gastric Cancer
Brief: Akeso Announced FDA Clearance Of Ind For Cd47 Monoclonal Antibody (Ak117) In Combination With Azacitidine In Myelodysplastic Syndromes
Brief: Akeso Posts HY Profit Attributable RMB2.53 Billion